We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01080638
Recruitment Status : Unknown
Verified March 2010 by Seoul National University Hospital.
Recruitment status was:  Recruiting
First Posted : March 4, 2010
Last Update Posted : March 4, 2010
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.

Condition or disease Intervention/treatment Phase
Myocardial Infarction Angioplasty Drug: glycoprotein IIb/IIIa inhibitor (abciximab) Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Study Start Date : October 2009
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack
Drug Information available for: Abciximab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Abciximab IC bolus
After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
Drug: glycoprotein IIb/IIIa inhibitor (abciximab)
patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Active Comparator: Abciximab IV bolus and 12hr continuous Drug: glycoprotein IIb/IIIa inhibitor (abciximab)
patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)


Outcome Measures

Primary Outcome Measures :
  1. In cardiac MRI- infarct size (total late enhancement volume at day 3-7) [ Time Frame: day 3~7 after percutaneous coronary intervention ]
    MRI: magnetic resonance image


Secondary Outcome Measures :
  1. in-hospital and after 1-months:the major adverse cardiovascular events : death, myocardial infarction, hospitalization for heart failure, myocardial ischemia, etc. [ Time Frame: 1 month ]
  2. b. major bleeding : Hemoglobin 4 or more reduction, 2-unit If you need more than two RBC transfusions, intracranial or retroperitoneal bleeding, urgent operation for bleeding complication. [ Time Frame: 1 month ]
    RBC: red blood cell

  3. TIMI III flow count /myocardial blush score after PCI [ Time Frame: 1 day ]
    TIMI: thrombolysis in myocardial infarction PCI: percutaneous coronary intervention

  4. At cardiac MRI : LV ejection fraction,LV end-systolic volume,LV end diastolic volume,regional wall motion score index [ Time Frame: 1 week ]
    LV: left ventricle

  5. Discharge, 1- month after comparing NT-proBNP [ Time Frame: 1 month ]
    NT-proBNP : N-terminal pro-B-Type natriuretic peptide


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • non-ST segment elevation acute myocardial infarction
  • within 48 hours presence of chest pain
  • Troponin-T or I positive before CAG
  • First myocardial infarction
  • will be performed coronary angioplasty

Exclusion Criteria:

  • under 18 years of age,80 years or older
  • Bleeding tendency
  • History of major surgery within 4 weeks
  • Major stroke within 2 years
  • Thrombocytopenia (<120,000 / uL)
  • Cardiogenic shock
  • Known allergy to aspirin, heparin, or abciximab
  • Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc)
  • Chronic atrial fibrillation
  • Pregnancy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01080638


Contacts
Contact: Myung-Ki Seo, MD 82-2-2072-3757 clotinab@gmail.com
Contact: Hyun-Jae Kang, Prof 82-2-2072-2279 nowkang@snu.ac.kr

Locations
Korea, Republic of
Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital Recruiting
Seoul, Korea, Republic of
Contact: Myung-Ki Seo, MD    82-2-2072-3757    clotinab@gmail.com   
Contact: Hyun-Jae Kang, Prof    82-2-2072-2279    nowkang@snu.ac.kr   
Sponsors and Collaborators
Seoul National University Hospital
Seoul National University Bundang Hospital
Investigators
Study Director: Hyun-Jae Kang, Prof Assistant professor, Cardiology, Department of internal medicine,Seoul National University Hospital
More Information

Responsible Party: Hyo-Soo Kim/ Prof, Director of Cardiac Catheterization Laboratory & Coronary Intervention of Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01080638     History of Changes
Other Study ID Numbers: H-0906-046-283
First Posted: March 4, 2010    Key Record Dates
Last Update Posted: March 4, 2010
Last Verified: March 2010

Keywords provided by Seoul National University Hospital:
abciximab
Myocardial Infarction
angioplasty
Platelet

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Non-ST Elevated Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Krestin
Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Abciximab
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Interferon Inducers
Radiation-Protective Agents
Protective Agents
Anticoagulants
Platelet Aggregation Inhibitors